About Harrow
Harrow is a publicly listed company based in Nashville (United States) founded in 2012. Ophthalmic products marketing services are provided by Harrow. It operates on a Direct-to-Consumer (D2C) and Professional Services model. The company has 382 employees. Harrow has completed 1 acquisition, including Melt Pharmaceuticals. Its website harrow.com draws about 19 thousand monthly visits. Harrow offers products and services including Ophthalmic Medications, Compounding Business, and Branded Therapies. Its focus areas include Pharmaceuticals and Ophthalmic Drugs. Its legal entity is Harrow, Inc. Its competitors include Cardinal Health, Moxie and Orbital Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Harrow, Inc. is dedicated to redefining eyecare through a comprehensive portfolio of ophthalmic pharmaceuticals. Solutions are developed to ensure safety, efficacy, and affordability for eyecare professionals and patients. The company operates in the rapidly growing ophthalmic market, offering essential medications, specialized compounding services, and branded therapies. Innovation and accessibility are prioritized to enhance patient outcomes and drive industry impact. Growth, operational excellence, and corporate responsibility are emphasized to shape the future of vision care. Access to high-quality, affordable treatments is ensured for the broader healthcare community.
- Headquarters Nashville, United States
- Employees 382
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website harrow.com
- Social LinkedIn
- Legal Name Harrow, Inc.
- Annual Revenue$272.3 M (USD)36.41as on Dec 31, 2025
- Net Profit-$5.14 M (USD)70.6as on Dec 31, 2025
- EBITDA$57.52 M (USD)151.27as on Dec 31, 2025
- Latest Funding Round$10.7M (USD), Post-IPO
May 2021
- Investors
- Employee Count382
- Investments & Acquisitions
Products & Services of Harrow
Harrow offers a comprehensive portfolio of products and services, including Ophthalmic Medications, Compounding Business, and Branded Therapies.
Essential medications for eyecare are provided by Harrow.
Specialized compounding solutions for eyecare are offered here.
Proven branded therapies for vision are delivered by Harrow.
Funding Insights of Harrow
- Total Rounds 1
- Last Round Post-IPO — $10.7M
- First Round $10.7M
(May 2021)
- Investors Count 1
All 1 funding rounds of Harrow with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2021 | $10.7M | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Harrow
Harrow has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include B. Riley Financial.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mergers, acquisitions, capital raising, and strategic advisory services are provided. | 1997 | brileyfin.com | Los Angeles, United States |
Investor details for Harrow
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Harrow
22 people are tracked at Harrow (9 in leadership, 4 in board & advisors, 9 in team); the tracked headcount is 382.
| Name | Role | Group |
|---|---|---|
Kim Barratt | Chief Talent Officer | Leadership |
Andrew R. Boll | Founder, Chief Financial Officer And Corporate Secretary | Leadership |
Mark L. Baum | Founder, Chairman, And CEO Of Harrow, Inc. | Leadership |
Carl Pottkotter | Vice President Of Technology | Leadership |
Amir Shojaei | Chief Scientific Officer | Leadership |
Mark Mannebach | Head of Regulatory Affairs & Pharmacovigilance | Leadership |
Tim Carder | National Director Of Training | Leadership |
Brett Burrell | Vice President Of Legal | Leadership |
Richard C. | Senior Director, Head Of Medical And Clinical | Leadership |
Marty Makary | Director | Board & advisors |
Perry J. Sternberg | Director | Board & advisors |
Richard L. Lindstrom | Director | Board & advisors |
R. Lawrence Van Horn | Director | Board & advisors |
Chintan Dalwadi | Laboratory Manager | Team |
Jada Sloss | Quality Assurance Trainer | Team |
Brandon Balmaceda | Accountant | Team |
Annie Dimuro | Talent Manager | Team |
Paulina Velazquez | Accounting Manager | Team |
Andrew Guanche | Senior Talent Acquisition Specialist | Team |
Anara Serikbaeva | Associate Manager Medical Affairs - Retina | Team |
2 more people are available in the full profile.
Complete people profiles for Harrow
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Harrow
Harrow is a publicly listed company on the NASDAQ with ticker symbol HROW in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Oct 2007
- Listed onNASDAQ: HROW
- Listed entityHarrow, Inc.
- Exchange sectorHealth technology
- ISINUS4158581094
- Share price$28.24 (-2.99% on the day) · 2026-10-13
- Market capitalisation$1.06B
- EPS (diluted, trailing year)$-1.00
- Volume (last session)800,969
Financials of Harrow
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $272.3M | -$5.1M | $57.5M |
| 2024 | $199.6M | -$17.5M | $22.9M |
| 2023 | $130.2M | -$24.4M | $12.9M |
| 2022 | $88.6M | -$14.1M | $5.5M |
| 2021 | $72.5M | -$18.0M | $4.2M |
Detailed financial statements for Harrow
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Harrow
Harrow has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Melt Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Pharmaceutical solutions are developed by Melt Pharmaceuticals in the US. | meltpharma.com | United States | 2018 | Sep 2025 | •••• |
Complete acquisition details for Harrow
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Harrow
4 dated milestones of Harrow across 18 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Founded Harrow is founded.
- Funding First funding round of $10.7M.
- Acquisition Acquires Melt Pharmaceuticals.
Competitors of Harrow
Harrow has 3 listed competitors in our database, 2 of them funded. They include Cardinal Health, Moxie and Orbital Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cardinalhealth.com | 1971 | Dublin, United States | 48,900 | Multiple healthcare products and services are provided to organizations. | ||
| joinmoxie.com | 2022 | New York, United States | $25.7M | Medical spa marketing services are provided by Moxie. | ||
| orbitaltx.com | 2022 | Yellow Springs, United States | $270M | Distributor of RNA medicines |
Detailed competitors of Harrow
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Harrow
The website of Harrow (harrow.com) receives about 18.6K visits a month and ranks #1,443,357 among all websites worldwide, #1,873 in Biotechnology and Pharmaceuticals.
- Monthly visits18.6K
▼ 5.9% vs previous month
- Unique visitors9K
per month
- Global rank#1,443,357
among all websites
- Category rank#1,873
Health · Biotechnology and Pharmaceuticals
- Bounce rate47%
- Pages per visit1.5
- Average visit15 sec
- DevicesDesktop 30% · Mobile 70%
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Harrow (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Harrow
Complete news archive for Harrow
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Harrow
Harrow was founded in 2012 and raised its 1st funding round 9 years after it was founded.
Harrow is headquartered in Nashville, United States. It is registered at Nashville, Tennessee, United States.
Harrow has 382 employees.
Annual revenue of Harrow is $272.3M as on Dec 31, 2025.
Harrow, Inc. is dedicated to redefining eyecare through a comprehensive portfolio of ophthalmic pharmaceuticals. Solutions are developed to ensure safety, efficacy, and affordability for eyecare professionals and patients. The company operates in the rapidly growing ophthalmic market, offering essential medications, specialized compounding services, and branded therapies. Innovation and accessibility are prioritized to enhance patient outcomes and drive industry impact. Growth, operational excellence, and corporate responsibility are emphasized to shape the future of vision care. Access to high-quality, affordable treatments is ensured for the broader healthcare community.
Harrow's top competitors include Cardinal Health, Moxie and Orbital Therapeutics.
Harrow offers Ophthalmic Medications, Compounding Business, and Branded Therapies.
Yes, Harrow is publicly traded on NASDAQ under the ticker symbol HROW.
Harrow has made 1 acquisition, including Melt Pharmaceuticals.
Harrow has 1 investor. Key investors include B. Riley Financial.
Harrow operates through Harrow, Inc..